Teneligliptin + Pioglitazone + Metformin ER is a combination oral antidiabetic therapy designed for effective management of type 2 diabetes mellitus. Teneligliptin 20mg – a DPP-4 inhibitor that enhances incretin hormone activity, improving insulin secretion and reducing glucagon release. Pioglitazone 15mg – a thiazolidinedione that improves insulin sensitivity in peripheral tissues, helping regulate blood sugar levels. Metformin 500mg (Extended Release) – a biguanide that lowers hepatic glucose production and increases glucose uptake in muscles. This triple combination is particularly useful for patients inadequately controlled on monotherapy or dual therapy, providing better glycemic control, reducing postprandial glucose spikes, and offering a once-daily extended-release convenience.
